The U.S. Supreme Court refused last week to make it easy for investors to recover on a “fraud on the market” theory.
The San Francisco-based 9th Circuit had ruled that Dura Pharmaceuticals could be sued if the price of its stock was inflated due to fraud, even if a later stock decline could not be attributed to any misrepresentation.
